“We plan to launch TEPEZZA in additional markets in 2026, expanding access to this important therapy globally.”

In context

“heumatologists, gastroenterologists, among others have prescribed Vuplisna. In addition to the more recent launches, continues to lead in NMOSD and remains the most prescribed FDA-approved Therapy In The U.S. For this condition. Supported by consistent new patient growth, and strong adherence across treatment cycles. TEPEZZA grew 3% to $1.9 billion in '25 driven by higher net selling price. Over 25,000 patients have received treatment since launch in The U.S. With growing interest from both new and returning prescribers. We continue to see increased prescribing by endocrinologists and a broadening base of specialists. In Japan, approximately 1,200 patients have been treated since launch, reflecting growing awareness of the burden of thyroid eye disease among both patients and prescribers. We plan to launch TEPEZZA in additional markets in 2026, expanding access to this important therapy globally. TADNIA sales were $459 million in 2025, an increase of 62% year over year driven by strong volume growth. More than 7,000 patients with ANCA-associated by vasculitis have now been treated with Tamios, with over 4,000 healthcare professionals prescribing the therapy since its launch in 2021. Anchor-associated vasculitis is a serious potentially life-threatening disease that can cause significant organ damage if not well controlled. And has limited therapeutic options. We remain confident that Tavneos is an important and effective medicine based on clinical data, real-world evidence, and its favorable benefit-risk profile. In inflammation, TestBio sales grew 52% year over year to nearly $1.5 billion for the full year. Taspire is well-positioned to reach more patients in The United States du”